Biomet provides description to FDA regarding advertising rights for Signature Personalized Individual Care system Biomet received a Caution Letter from the U.S. The business hasn’t received a formal response to its August 3rd letter to the FDA. Biomet is focused on dealing with the FDA to solve the concern in the very best interests of individuals and their doctors without disruption to individual treatment.RaQualia and CJ signed a Memorandum of Understanding in June 2010 to establish a strategic alliance in innovative gastrointestinal therapies. This is the 2nd permit contract between RaQualia and CJ following the license agreement for Acid Pump Antagonist in September 2010.. Anti-diabetic medication activates brain sensors, promotes weight gain Medication used to treat patients with type II diabetes activates sensors on human brain cells that increase hunger, leading to people taking this drug to gain more fat, according to experts at Georgia State University, Oregon Health and Science University, Georgia Regents University and Charlie Norwood Veterans Administration Medical Center. The scholarly study, published on March 18 in The Journal of Neuroscience, describes a fresh way to affect hunger in the mind and helps to explain why people taking a class of medicines for type II diabetes gain more fat.